Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/21039
DC FieldValueLanguage
dc.contributor.authorWägner, Ana Maríaen_US
dc.contributor.authorMiranda Calderín, Guillermoen_US
dc.contributor.authorUgarte-Lopetegui, Miren Arantzaen_US
dc.contributor.authorMarrero-Santiago, Héctoren_US
dc.contributor.authorSuárez-Castellano, Lauraen_US
dc.contributor.authorAlberiche Ruano, Maria Del Pinoen_US
dc.contributor.authorCastillo-García, Nuriaen_US
dc.contributor.authorLópez-Madrazo, María Joséen_US
dc.contributor.authorAlemán, Carolinaen_US
dc.contributor.authorMartínez-Mancebo, Carlaen_US
dc.contributor.authorLópez Ríos, Lauraen_US
dc.contributor.authorDíez del Pino, Aliciaen_US
dc.contributor.authorNovoa Mogollón, Franciscoen_US
dc.date.accessioned2017-03-22T03:30:59Z-
dc.date.accessioned2018-03-16T09:14:07Z-
dc.date.available2017-03-22T03:30:59Z-
dc.date.available2018-03-16T09:14:07Z-
dc.date.issued2016en_US
dc.identifier.issn2451-8654en_US
dc.identifier.otherScopus-
dc.identifier.urihttp://hdl.handle.net/10553/21039-
dc.description.abstractPreclinical studies and small clinical trials suggest that glucagon-like peptide 1 (GLP1) may have a positive effect on ventricular function. Liraglutide is a GLP1-analogue used in the treatment of type 2 diabetes. LIPER2 is a phase IV, randomised, double-blind, placebo-controlled, parallel-design trial, assessing the effect of 6 months’ liraglutide 1.8 mg/d on measures of cardiac function and physical performance in patients with type 2 diabetes. A total of 30 patients with type 2 diabetes will be included, if their HbA1c is between 7 and 10% while on oral agents (including metformin if tolerated and not contraindicated), a maximum of 2 intermediate or long-acting insulin injections per day or a combination of both. After their baseline examinations, patients are randomised to receive a daily subcutaneous liraglutide or placebo injection (titrated to 1.8 mg/d if tolerated) for 6 months. The primary end-point is the maximal oxygen consumption during cycle ergometry at the end of the study period. Other end-points include distance covered during a 6-min walk test, left ventricular ejection fraction and other measures of ventricular systolic and diastolic functions assessed by echocardiography, heart rate, blood pressure, pro-brain natriuretic peptide, C-reactive protein, HbA1c, lipids, apolipoprotein B, body weight and waist girth. Safety end-points include adverse event reporting, blood count, kidney and liver function, amylase, lipase, electrolytes, calcitonin, CA19.9 and pregnancy test for fertile women. At the time of this report, recruitment is still ongoing. Results are expected to be reported in December 2016.en_US
dc.formatapplication/pdf-
dc.languageengen_US
dc.relation.ispartofContemporary Clinical Trials Communicationsen_US
dc.rightsby-nc-nd-
dc.sourceContemporary Clinical Trials Communications[ISSN 2451-8654],v. 4, p. 46-51, (Diciembre 2016)en_US
dc.subject320502 Endocrinologíaen_US
dc.subject.otherRandomised controlled trialen_US
dc.subject.otherErgometryen_US
dc.subject.otherMaximal oxygen consumptionen_US
dc.subject.otherVentricular functionen_US
dc.subject.otherDiabetesen_US
dc.subject.otherGLP1-agonisten_US
dc.titleEffect of liraglutide on physical performance in type 2 diabetes (LIPER2): A randomised, double-blind, controlled trialen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.conctc.2016.06.007en_US
dc.identifier.scopus2-s2.0-84977653628-
dc.identifier.scopus84977653628-
dc.identifier.isi000399161400008-
dc.contributor.authorscopusid7401456520-
dc.contributor.authorscopusid6504769712-
dc.contributor.authorscopusid57190138377-
dc.contributor.authorscopusid55953726600-
dc.contributor.authorscopusid11940471400-
dc.contributor.authorscopusid57190139526-
dc.contributor.authorscopusid57190136692-
dc.contributor.authorscopusid26536142100-
dc.contributor.authorscopusid19638685500-
dc.contributor.authorscopusid57190136716-
dc.contributor.authorscopusid33068166900-
dc.contributor.authorscopusid6506293404-
dc.contributor.authorscopusid57041246400-
dc.identifier.crisid15427;1545;-;-;-;-;-;-;-;-;-;-;422-
dc.description.lastpage51en_US
dc.description.firstpage46en_US
dc.relation.volume4en_US
dc.investigacionCiencias de la Saluden_US
dc.rights.accessrightsAcceso libre-
dc.type2Artículoen_US
dc.contributor.daisngid450201-
dc.contributor.daisngid7989267-
dc.contributor.daisngid16142914-
dc.contributor.daisngid8309483-
dc.contributor.daisngid8504772-
dc.contributor.daisngid13340600-
dc.contributor.daisngid11703935-
dc.contributor.daisngid8554851-
dc.contributor.daisngid20091221-
dc.contributor.daisngid12317913-
dc.contributor.daisngid1964185-
dc.contributor.daisngid22058530-
dc.contributor.daisngid4992898-
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Wagner, AM-
dc.contributor.wosstandardWOS:Miranda-Calderin, G-
dc.contributor.wosstandardWOS:Ugarte-Lopetegui, MA-
dc.contributor.wosstandardWOS:Marrero-Santiago, H-
dc.contributor.wosstandardWOS:Suarez-Castellano, L-
dc.contributor.wosstandardWOS:Alberiche-Ruano, MD-
dc.contributor.wosstandardWOS:Castillo-Garcia, N-
dc.contributor.wosstandardWOS:Lopez-Madrazo, MJ-
dc.contributor.wosstandardWOS:Aleman, C-
dc.contributor.wosstandardWOS:Martinez-Mancebo, C-
dc.contributor.wosstandardWOS:Lopez-Rios, L-
dc.contributor.wosstandardWOS:del Pino, AD-
dc.contributor.wosstandardWOS:Novoa-Mogollon, FJ-
dc.date.coverdateDiciembre 2016en_US
dc.identifier.supplement15427;1545;-;-;-;-;-;-;-;-;-;-;422-
dc.identifier.supplement15427;1545;-;-;-;-;-;-;-;-;-;-;422-
dc.identifier.supplement15427;1545;-;-;-;-;-;-;-;-;-;-;422-
dc.identifier.supplement15427;1545;-;-;-;-;-;-;-;-;-;-;422-
dc.identifier.supplement15427;1545;-;-;-;-;-;-;-;-;-;-;422-
dc.identifier.ulpgces
dc.description.sjr0,147
dc.description.sjrqQ3
item.grantfulltextopen-
item.fulltextCon texto completo-
crisitem.author.deptDiabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptCiencias Médicas y Quirúrgicas-
crisitem.author.deptCiencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-7663-9308-
crisitem.author.orcid0000-0001-9642-3996-
crisitem.author.orcid0000-0003-3629-8120-
crisitem.author.orcid0000-0003-3629-8120-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameWägner, Anna Maria Claudia-
crisitem.author.fullNameMiranda Calderín, Guillermo-
crisitem.author.fullNameAlberiche Ruano, Maria Del Pino-
crisitem.author.fullNameNovoa Mogollón, Francisco-
crisitem.author.fullNameNovoa Mogollón, Francisco-
Appears in Collections:Artículos
Thumbnail
Adobe PDF (309,3 kB)
Show simple item record

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.